CRP as an early indicator for anastomotic leakage after esophagectomy for cancer: a single tertiary gastro-esophageal center study.


Journal

Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285

Informations de publication

Date de publication:
15 Nov 2023
Historique:
received: 30 07 2023
accepted: 07 11 2023
medline: 16 11 2023
pubmed: 15 11 2023
entrez: 14 11 2023
Statut: epublish

Résumé

To determine the relationship between postoperative C-reactive protein (CRP) as an early indicator of anastomotic leakage (AL) after esophagectomy for esophageal cancer. We reviewed patients diagnosed with esophageal or esophagogastric junctional cancer who underwent esophagectomy between 2006 and 2022 at the Karolinska University Hospital, Stockholm, Sweden. Multivariable logistic regression models estimated relative risk for AL by calculating the odds ratio (OR) with a 95% confidence interval (CI). The cut-off values for CRP were based on the maximum Youden's index using receiver operating characteristic curve analysis. In total, 612 patients were included, with 464 (75.8%) in the non-AL (N-AL) group and 148 (24.2%) in the AL group. Preoperative body mass index and the proportion of patients with the American Society of Anesthesiologists physical status classification 3 were significantly higher in the AL group than in the N-AL group. The median day of AL occurrence was the postoperative day (POD) 8. Trends in CRP levels from POD 2 to 3 and POD 3 to 4 were significantly higher in the AL than in the N-AL group. An increase in CRP of ≥ 4.65% on POD 2 to 3 was an independent risk factor for AL with the highest OR of 3.67 (95% CI 1.66-8.38, p = 0.001) in patients with CRP levels on POD 2 above 211 mg/L. Early changes in postoperative CRP levels may help to detect AL early following esophageal cancer surgery.

Identifiants

pubmed: 37964057
doi: 10.1007/s00423-023-03176-w
pii: 10.1007/s00423-023-03176-w
pmc: PMC10645624
doi:

Substances chimiques

C-Reactive Protein 9007-41-4

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

436

Informations de copyright

© 2023. The Author(s).

Références

Dis Esophagus. 2021 Feb 10;34(2):
pubmed: 33565590
Dis Esophagus. 2021 Mar 8;34(3):
pubmed: 32901259
Ann Surg. 2014 Aug;260(2):259-66
pubmed: 24743609
Lancet Oncol. 2011 Jul;12(7):681-92
pubmed: 21684205
Dis Esophagus. 2021 Jan 11;34(1):
pubmed: 32476017
Ann Thorac Surg. 2021 Jul;112(1):255-263
pubmed: 33075324
Ann Surg. 2015 Aug;262(2):286-94
pubmed: 25607756
Dis Esophagus. 2018 Nov 1;31(11):
pubmed: 29939229
Surg Today. 2012 Jan;42(2):141-6
pubmed: 22094435
Surgery. 2016 Jul;160(1):191-203
pubmed: 27067160
Lancet. 2012 May 19;379(9829):1887-92
pubmed: 22552194
Ann Surg. 2019 Apr;269(4):621-630
pubmed: 30308612
J Thorac Dis. 2017 Oct;9(10):3693-3702
pubmed: 29268376
J Minim Access Surg. 2019 Jan-Mar;15(1):46-50
pubmed: 29595182
Dis Esophagus. 2021 Sep 9;34(9):
pubmed: 33367786
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Langenbecks Arch Surg. 2022 Dec;407(8):3377-3386
pubmed: 36207546
PLoS One. 2015 Jul 15;10(7):e0132995
pubmed: 26177542
Endosc Int Open. 2016 Apr;4(4):E420-6
pubmed: 27092321
Ann Surg. 2019 Feb;269(2):291-298
pubmed: 29206677
Ann Thorac Cardiovasc Surg. 2004 Apr;10(2):71-5
pubmed: 15209546
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Ann Surg Oncol. 2022 Sep;29(9):5609-5621
pubmed: 35752726
Br J Surg. 2015 May;102(6):590-8
pubmed: 25776855
PLoS One. 2018 Dec 17;13(12):e0209272
pubmed: 30557392
Ann Surg. 2015 Dec;262(6):972-80
pubmed: 26469952
BMC Surg. 2020 Dec 9;20(1):324
pubmed: 33298038
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
J Gastrointest Surg. 2012 Jun;16(6):1083-95
pubmed: 22419007

Auteurs

Motonari Ri (M)

Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Surgery and Oncology, Karolinska Institutet, Hälsovägen 13, 141 57, Huddinge, Stockholm, Sweden.
Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.

Antonios Tzortzakakis (A)

Department for Clinical Science, Intervention and Technology (CLINTEC), Division of Radiology, Karolinska Institutet, Stockholm, Sweden.
Department of Medical Radiation Physics and Nuclear Medicine, Functional Unit of Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.

Ira Sotirova (I)

Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Surgery and Oncology, Karolinska Institutet, Hälsovägen 13, 141 57, Huddinge, Stockholm, Sweden.
Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Surgery, Umeå University Hospital, Umeå, Sweden.

Andrianos Tsekrekos (A)

Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Surgery and Oncology, Karolinska Institutet, Hälsovägen 13, 141 57, Huddinge, Stockholm, Sweden.
Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.

Fredrik Klevebro (F)

Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Surgery and Oncology, Karolinska Institutet, Hälsovägen 13, 141 57, Huddinge, Stockholm, Sweden.
Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.

Mats Lindblad (M)

Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Surgery and Oncology, Karolinska Institutet, Hälsovägen 13, 141 57, Huddinge, Stockholm, Sweden.
Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.

Magnus Nilsson (M)

Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Surgery and Oncology, Karolinska Institutet, Hälsovägen 13, 141 57, Huddinge, Stockholm, Sweden.
Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.

Ioannis Rouvelas (I)

Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Surgery and Oncology, Karolinska Institutet, Hälsovägen 13, 141 57, Huddinge, Stockholm, Sweden. ioannis.rouvelas@ki.se.
Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden. ioannis.rouvelas@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH